UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 101

Sortiert nach

Real-world Management of CML: Outcomes and Treatment Patterns

Current hematologic malignancy reports, 2023-10, Vol.18 (5), p.167-175

2023

Volltextzugriff (PDF)

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Clinical cancer research, 2014-01, Vol.20 (2), p.490-498

2014

Volltextzugriff (PDF)

Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective

Journal of health economics and outcomes research (Online), 2022-08, Vol.9 (2), p.30-36

2022

Volltextzugriff (PDF)

Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making

Best practice & research. Clinical haematology, 2021-03, Vol.34 (1), p.101240-101240, Article 101240

Atallah, Ehab L.

2021

Volltextzugriff (PDF)

Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States

Journal of health economics and outcomes research (Online), 2022-08, Vol.9 (2), p.19-29

2022

Volltextzugriff (PDF)

Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy

Leukemia research, 2023-09, Vol.132, p.107348-107348, Article 107348

2023

Volltextzugriff (PDF)

Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates

Leukemia & lymphoma, 2021-06, Vol.62 (7), p.1730-1739

2021

Volltextzugriff (PDF)

Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice

American Society of Clinical Oncology educational book, 2022-04, Vol.42 (42), p.1-613

2022

Volltextzugriff (PDF)

Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia

Leukemia & lymphoma, 2021-01, Vol.62 (1), p.158-166

2021

Volltextzugriff (PDF)

Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective

Leukemia & lymphoma, 2019-05, Vol.60 (6), p.1476-1484

2019

Volltextzugriff (PDF)

Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia

Blood advances, 2023-04, Vol.7 (7), p.1279-1285

2023

Volltextzugriff (PDF)

Clarifying the use of ruxolitinib in patients with myelofibrosis

Oncology (Williston Park, N.Y.), 2013-07, Vol.27 (7), p.706-714

2013

Volltextzugriff (PDF)

Implementation and evaluation of high-dose methotrexate administration guidelines

Journal of oncology pharmacy practice, 2019-10, Vol.25 (7), p.1675-1681

2019

Volltextzugriff (PDF)

Sequential salvage chemotherapy and lintuzumab-Ac225 results in deep responses and prolonged survival in adverse risk relapsed/refractory AML and in AML patients that received prior venetoclax therapy

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e19030-e19030

2023

Volltextzugriff (PDF)

Assessment of Comorbidities and Their Association with Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL)Using Various Comorbidity-Based Scoring Systems

Blood, 2022-11, Vol.140 (Supplement 1), p.6035-6036

2022

Volltextzugriff (PDF)

Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood, 2022-11, Vol.140 (Supplement 1), p.11020-11021

2022

Volltextzugriff (PDF)

Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy

Blood, 2020-11, Vol.136 (Supplement 1), p.8-9

2020

Volltextzugriff (PDF)

ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS7082-TPS7082

2023

Volltextzugriff (PDF)

Lintuzumab-Ac225 in Combination with CLAG-M Yields High MRD (-) Responses in R/R AML with Adverse Features: Interim Results of a Phase I Study

Blood, 2021-11, Vol.138 (Supplement 1), p.3414-3414

2021

Volltextzugriff (PDF)

ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)

Blood, 2022-11, Vol.140 (Supplement 1), p.6784-6786

2022

Volltextzugriff (PDF)

Population Level Outcomes of Chronic Lymphocytic Leukemia in the Era of Targeted Agents- Analysis of Surveillance Epidemiology and End Results (SEER) Database

Blood, 2019-11, Vol.134 (Supplement_1), p.1757-1757

2019

Volltextzugriff (PDF)

Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study

Blood, 2022-11, Vol.140 (Supplement 1), p.6765-6766

2022

Volltextzugriff (PDF)

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

Blood, 2022-11, Vol.140 (Supplement 1), p.157-158

2022

Volltextzugriff (PDF)

Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective

Journal of health economics and outcomes research (Online), 2022-07, Vol.9 (2), p.30-36

2022

Volltextzugriff (PDF)

Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates

Blood, 2019-11, Vol.134 (Supplement_1), p.2208-2208

2019

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(98)

Publikationsform

Artikel
(101)

Sprache

Englisch
(101)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Oncology
(12)
Hematology
(9)
Humans
(9)
Aged
(4)
Chronic Myeloid Leukemia
(4)
Acute Myeloid Leukemia
(3)
Aged, 80 And Over
(3)
Female
(3)
Leukemia, Myeloid, Acute - Drug Therapy
(3)
Male
(3)
Middle Aged
(3)
Prognosis
(3)
Retrospective Studies
(3)
Treatment Outcome
(3)
Adult
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Business & Economics
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Real-world Management of CML: Outcomes and Treatment Patterns

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective

Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making

Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States

Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy

Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates

Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice

Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia

Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective

Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia

Clarifying the use of ruxolitinib in patients with myelofibrosis

Implementation and evaluation of high-dose methotrexate administration guidelines

Sequential salvage chemotherapy and lintuzumab-Ac225 results in deep responses and prolonged survival in adverse risk relapsed/refractory AML and in AML patients that received prior venetoclax therapy

Assessment of Comorbidities and Their Association with Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL)Using Various Comorbidity-Based Scoring Systems

Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)

Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy

ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)

Lintuzumab-Ac225 in Combination with CLAG-M Yields High MRD (-) Responses in R/R AML with Adverse Features: Interim Results of a Phase I Study

ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)

Population Level Outcomes of Chronic Lymphocytic Leukemia in the Era of Targeted Agents- Analysis of Surveillance Epidemiology and End Results (SEER) Database

Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective

Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates

Suchergebnisse filtern